Back to News
Market Impact: 0.2
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
Source: GlobeNewswire
Healthcare & Biotech
The first patient has completed a 28-day treatment course with darizmetinib, marking an early clinical-development milestone. A second Phase 1b pilot cohort is expected to enroll 10 patients and complete by Q4 2026, with efficacy and safety results still pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum